[144] Denali Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Denali Therapeutics (DNLI) reported a Form 144 notice showing an intended sale of 806 shares of common stock, representing restricted stock units acquired on 08/11/2025. The aggregate market value of the proposed sale is $10,655.32, with an approximate sale date of 08/13/2025 on NASDAQ through Morgan Stanley Smith Barney.

The filing also discloses a sale earlier in the three‑month window by Carole Ho of 2,937 shares on 08/12/2025 for gross proceeds of $39,880.52. The notice includes the standard representation that the seller does not possess undisclosed material information about the issuer.

Insights

Securities Analyst

TL;DR: Small insider sales disclosed; amounts are minor versus total shares outstanding and unlikely to be materially market moving.

The Form 144 shows a proposed sale of 806 RSU shares valued at $10,655.32, to be executed on 08/13/2025 on NASDAQ via Morgan Stanley Smith Barney. The filing also reports a prior sale of 2,937 shares on 08/12/2025 generating $39,880.52. With total shares outstanding reported as 146,212,278, these transactions are extremely small relative to the company's share base. From a market-impact perspective, these disclosures appear routine and compliance‑oriented rather than indicative of material change in company fundamentals.

Corporate Governance Expert

TL;DR: Disclosure follows regulatory procedure; raises routine governance considerations but no evident governance red flags.

The form documents lawful disposition of equity originated as Restricted Stock Units on 08/11/2025 and includes the seller's attestation about lack of undisclosed material information. The sale routing through a major broker and the inclusion of prior insider sales in the three‑month period align with standard disclosure practices. There is no information in the filing suggesting unusual timing, structured plans, or compliance failures based on the data provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	806	10655.32	146212278	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2025	Restricted Stock Units	Issuer			806	08/11/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CAROLE HO 161 Oyster Point Blvd. South San Francisco CA 94080	Common	08/12/2025	2937	39880.52

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the DNLI Form 144 disclose?

The Form 144 discloses a proposed sale of 806 common shares (RSUs) valued at $10,655.32, with an approximate sale date of 08/13/2025 on NASDAQ.

Who is the broker handling the proposed sale in the DNLI filing?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York, NY.

Were there any insider sales by the same account in the past three months for DNLI?

Yes. The filing reports a prior sale by Carole Ho of 2,937 shares on 08/12/2025 for gross proceeds of $39,880.52.

What type of equity is being sold according to the DNLI Form 144?

The securities to be sold are Common stock acquired as Restricted Stock Units on 08/11/2025.

How many shares outstanding does DNLI report in this filing?

The filing lists 146,212,278 shares outstanding.